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Abstract
Background: Osteosarcoma (OS) is the most common primary malignant tumor of bone in children and adolescents. 
However, the knowledge in diagnostic modalities has progressed less. To identify new biomarkers for the early 
diagnosis of OS as well as for potential novel therapeutic candidates, we performed a sub-cellular comparative 
proteomic research.
Methods: An osteosarcoma cell line (MG-63) and human osteoblastic cells (hFOB1.19) were used as our comparative 
model. Plasma membrane (PM) was obtained by aqueous two-phase partition. Proteins were analyzed through iTRAQ-
based quantitative differential LC/MS/MS. The location and function of differential proteins were analyzed through GO 
database. Protein-protein interaction was examined through String software. One of differentially expressed proteins 
was verified by immunohistochemistry.
Results: 342 non-redundant proteins were identified, 68 of which were differentially expressed with 1.5-fold difference, 
with 25 up-regulated and 43 down-regulated. Among those differential proteins, 69% ware plasma membrane, which 
are related to the biological processes of binding, cell structure, signal transduction, cell adhesion, etc., and interaction 
with each other. One protein--CD151 located in net nodes was verified to be over-expressed in osteosarcoma tissue by 
immunohistochemistry.
Conclusion: It is the first time to use plasma membrane proteomics for studying the OS membrane proteins according 
to our knowledge. We generated preliminary but comprehensive data about membrane protein of osteosarcoma. 
Among these, CD151 was further validated in patient samples, and this small molecule membrane might be a new 
target for OS research. The plasma membrane proteins identified in this study may provide new insight into 
osteosarcoma biology and potential diagnostic and therapeutic biomarkers.
Background
Osteosarcoma is the third most common cancer in child-
hood and adolescents and the most common primary
malignancy of bone. With combination treatment (neo-
adjuvant chemotherapy, surgery, and adjuvant chemo-
therapy), the 5-year survival for patients who do not have
metastatic disease at diagnosis is 60% to 70% [1,2]. How-
ever, for patients with metastatic disease at diagnosis or
with tumors showing a poor response to chemotherapy,
the prognosis is still unsatisfactory (5-year disease-spe-
cific survival rates, 20%-40%), even with dose-intensive or
high-dose chemotherapy [3]. Thus, it is of great impor-
tance to develop new targeted therapeutic strategies
based on OS-specific proteins and find more biomarkers
for diagnosis as well as prognosis prediction of this lethal
disease.
At present, comparative proteomics provide a powerful
approach in screening for alterations in protein levels and
post-translational modifications that are associated with
tumors and has culminated in the identification of many
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potential new therapeutic targets and an abundance of
cancer-related biomarkers. However, global proteomic
profiling of human OS developed very late and slowly. To
our knowledge, only a few papers have reported compar-
ative proteome research in OS, including our previous
data obtain by comparative proteomic analysis of patient
sera [4-8]. In some of these researches, tissue and cell
lines were used. But due to the complexity and difference
of proteome, low copy proteins and membrane proteins
were usually undetected in whole cell or tissue. Recently,
many proteomic investigations have focused on subcellu-
lar compartments [9,10]. The plasma membrane (PM) is
an organized system serving as a structural and commu-
nication interface for exchanges of information and sub-
stances with the extracellular environment. The proteins
on the PM act as 'doorbells' and 'doorways' playing crucial
roles in cell function including intercellular communica-
tion, cellular development, cell migration, and drug resis-
tance [6,11-13]. So it is important to systematically study
the PM proteins involved in OS.
PM proteomic research of OS faces three challenges: 1)
excluding the individual difference; 2) obtaining adequate
and purified PM for proteomic analysis; 3) identifying
low abundant proteins. In this study, MG-63 (an OS cell
line) and hFOB1.19 (a SV40-immortalized normal osteo-
blastic cell line) were used as a comparative model for
studying the proteins related to OS. PM was separated by
aqueous two-phase partition. Proteins were analyzed by
iTRAQ-based LC-MS/MS-based proteomics to exclude
the protein bias in two-dimensional electrophoresis
(2DE) [14,15]. 342 proteins were identified, out of which,
69 proteins were found to be differentially expressed for
more than 1.5-fold. The expression of CD 151 antigen
was further evaluated by immunohistochemistry in clini-
cal samples. It's the first time the PM proteomics of OS
was studied and CD151 antigen was found to be over-
expressed in cell lines and confirmed its overproduction
in OS clinical tissue, which was also observed to be up-
regulated in breast cancer [16,17] but down-regulated in
colorectal cancer [18]. Our results showed that sub-cellu-
lar proteomics is a useful method for selecting OS bio-
markers and CD151 might be potential target for
diagnosis and treatment of OS.
Methods
Cell culture
Human osteosarcoma cell lines MG-63, and the normal
osteoblastic cell line hFOB1.19 (expressing SV40 large T
antigen) were originally obtained from the American
Type Culture Collection (Manassas, VA, USA). The cell
lines were cultured as previously described [8] with some
modification. Briefly, the cell lines were cultured in Dul-
becco's Modified Eagle Medium (DMEM) (Invitrogen)
with 10% FBS. For human osteoblastic cell line hFOB1.19,
a 1:1 Ham's F12 medium was added to DMEM without
phenol red and with 2.5 mmol/L L-glutamine and 0.3 mg/
mL G418. All cultures were maintained in 10 cm diame-
ter dishes in a humidified atmosphere of 5% CO2 at 37°C.
MG-63 cells were subcultured every 2 to 3 days, and
hFOB1.19 cells were subcultured every 4 to 5 days. Fur-
thermore, the same Ham's F12 medium and DMEM with
10% FBS without G418 was used to incubate the two cell
lines for the least 24 hours before harvesting them for
membrane extraction to exclude any unexpected affect
that the difference between culture medium will cause.
About 108 cells were collected and used for PM separa-
tion.
Patient tissue samples
All patient tissue and clinical information was collected
with patients' consent after permitted by Ethics Commit-
tee of Tongji University. Eleven archival sections of form-
alin-fixed, paraffin-embedded primary osteosarcoma and
their respective adjacent non-tumorous tissue were col-
lected.
Preparation of plasma membrane
The PM was isolated as previously described [19,20]. All
steps were carried out at 4°C. Briefly, adherent cells (108)
were washed three times with PBS, scraped using a plas-
tic cell lifter, and broken in 1 mL solution containing 0.2
mM EDTA, 1 mM NaHCO3 using a glass homogenizer.
The nuclear and unbroken cells were removed through
200 g, the supernatant was collected, and centrifuged for
30 min at 25000 rpm. The cell pellets were resuspended
in 1 mM NaHCO3 in an approximate ratio of 1 ml per 5 ×
108 cells and used for PM separation by two-phase sys-
tems [20]. 2 g of suspended cell pellets was added to the
top of 14 g of the dextran-poly(ethylene glycol) mixture
(6.6% Dextran T500, 6.6% PEG 3350,0.2 M K3PO4,
pH7.2). After mixed for 40 times, the tube was centri-
fuged for 5 min at 750 g. The PM-enriched upper phase
was collected and purified again as before. The upper
phase was diluted 5-fold with 1 mM sodium bicarbonate,
and centrifuged at 100 000 g for 2 h in a SW32 rotor. The
pellets were collected and used for purification check and
proteomics.
Protein Digest, iTRAQ Labeling, and Strong Cation 
Exchange Fractionation
iTRAQ labeling was done according to the kit protocol
(Applied Biosystems Inc., Foster City, CA) and the previ-
ously reported by Jonghwa Jin [21,22]. Protein (100 μg)
from the PM of MG-3 and hFOB1.19 cell lines was ace-
tone precipitated overnight at -20°C and resuspended in
30 μL iTRAQ™ Dissolution Buffer (ABI, Foster City,
USA). After reduction and alkylation, proteins solutions
were digested overnight at 37°C with sequence gradeZhang et al. BMC Cancer 2010, 10:206
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modified trypsin (Promega) (1:10). The peptides were
pooled, desalted with Sep-Pak Cartridge (Waters) and
fractionated by Strong Cation Exchange (SCX) chroma-
tography on an Ultimate HPLC system (LC Packings)
using a Column(5 μm, 300 Å, 0.5 × 23 mm, Waters). Pep-
tides were eluted with a linear gradient of 0-500 mM KCl
(25% v/v acetonitrile, 10 mM KH2PO4, pH 2.8) for 60 min
at a flow rate of 200 μl/min. 15 fractions were collected.
The iTRAQ experiments were carried out twice: the first
experiment compared MG-63 cells (115 reporter ions)
and hFOB1.19 (116 reporters), while the second experi-
ment was performed using MG-63 (115 reporters),
hFOB1.19 (114 reporters).
LC-MS Analysis
Each SCX fraction was dried down, dissolved in 0.1% for-
mic acid, and analyzed on Qstar Pulsar™ (Applied Biosys-
tems-MDS Sciex). Peptides were separated on a reverse-
phase column packed with ZORBAX 300SB-C18 enrich-
ment column (5 μm, 300 Å, 0.5 × 23 mm, Waters) and
separated by a 75-μm-internal diameter PepMap RP col-
umn from LC Packings packed with 3-μm C18 beads with
100-Å pores. Buffer A: 5%ACN, 95% water, 0.1% FA and
Buffer B: 95%ACN, 5% water, 0.1%FA. The flow rate used
for separation on the RP column was 400 nl/min with
gradient 5%-45% during 90 min. MS data was acquired
automatically using Analyst QS 1.0 software Service Pack
8 (ABI/MDS SCIEX, Concord, Canada). An analysis sur-
vey scans were acquired from 400-1800 with up to 6 pre-
cursors selected for MS/MS from m/z 100-2000. The two
most intense peaks over 30 counts, with a charge state 2-4
were selected for fragmentation. Curtain gas was set at
10, nitrogen was used as the collision gas, and the ioniza-
tion tip voltage was 4000 V.
Data analysis
Ratios of the 114.1, 115.1 and 116.1 amu signature mass
tags generated upon MS/MS fragmentation from the
iTRAQ™-labeled tryptic peptides were calculated using
Protein Pilot (ABI, USA) (version 2.0.1) (ABI) in Analyst.
The MS and MS/MS tolerances were set to 0.2 Da. The
IPI databases was used for searching iTRAQ™-identified
peptides. Methyl methanethiosulphonate modification of
cysteines was used as a fixed modification, and one
missed tryptic cleavage was allowed. All proteins identi-
fied must have ≥95% confidence and the protein confi-
dence threshold cutoff was set to 1.3 (unused) with at
least more than one peptide above the 95% confidence
level. The true value for the average ratio was expressed
as an error factor (EF = 10(95% confidence interval)) and calcu-
lated according to the reports [23,24]. An EF <2 was set
for the quantification quality to be satisfied. In addition, a
p-value < 0.05 was significant for protein quantification.
To designate significant changes in protein expression,
fold-changes >1.5 or <0.66 were set as cutoff values. Fur-
thermore, in order to decrease the artificial error, results
were "auto" bias corrected using IT115: IT114 of 1.3564.
The peptide and proteins were exported, and saved as
excel files.
Bioinformatics
The theoretical isoelectric point (pI) and molecular
weight (MW) and Grand average of hydropathicity
(GRAVY) were calculated through inhouse developed
software. The sub-cellular location and function of the
i d e n t i f i e d  p r o t e i n s  w e r e  e l u c i d a t e d  b y  U n i P r o t  k n o w l -
edgebase (Swiss-Prot/TrEMBL) and Gene Ontology
Database. The mapping of putative transmembrane heli-
ces (TMHs) in the identified proteins was carried out
using the transmembrane hidden Markov model
(TMHMM) algorithm, available at http://www.cbs.
dtu.dk/services/TMHMM. A protein-protein interaction
network was done by STRING software through input-
ting IPI number http://string.embl.de.
Immunohistochemistry
Immunohistochemistry (IHC) was carried as previously
described [25,26]. The sections were then dehydrated by
passage through a series of ethanol and embedded in par-
affin, and incubated with anti-CD151 (Abcam, clone
11G5a Cambridge, MA, USA) in a humidified chamber
overnight and washed in PBS for 3 times followed by
incubated with secondary antibody 30 min and detected
using a liquid 3, 3'-diaminobenzidine (DAB) staining kit
from Gene Tech Company. Sections were counterstained
with Hematoxylin-exon, dehydrated, mounted in Per-
mount (Fisher Scientific) and four representative fields
were captured digitally by light microscopy using an
Olympus BX40 equipped with a logenE PAS9000. The
antigen density was counted by Image-Pro Plus v6.2 soft-
ware (Media Cybernetics, Inc., Bethesda, MD). The den-
s i t y  o f  a l l  p o s i t i v e  s t a i n i n g  i n  e a c h  p h o t o g r a p h  w a s
measured and summed up then normalized with total cell
number counted to give an expression rate of antigen.
Statistical Analysis
Protein expression levels of immunohistochemistry were
compared between groups with two-way T-test.
Results
Production and characterization of PM derived from cell 
lines
Although the growth characteristic of the two cell lines--
MG-63 and hFOB1.19 is different, the cells were cultured
with similar nutrition. In order to decrease the difference
caused by culture nutrition, the cells were cultured for at
least 24 hours in the same nutrition before they were col-
lected. About 108 cells were used for PM separation. InZhang et al. BMC Cancer 2010, 10:206
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this work, a combination of differential centrifugation
and aqueous two-phase partitioning [20] was used to sep-
arate plasma membrane. Two phases were obtained after
centrifugation, including upper and down-phase. Frac-
tions containing PM were determined based on the
enrichment of a PM marker enzyme--Na+/K+ ATPase and
the decrease of a mitochondrial marker-Prohibitin. As
shown in Figure 1, PM was enriched in the upper phase
by comparing the signal strength of upper phase (Nor U
and MG U) with that of down phase (Nor D and MG D).
According to the results analyzed by Image J software
http://rsb.info.nih.gov/ij, PM was enriched for 11.2 or
15.3-fold in upper phase and 6.5 or 3.9-fold in down-
phase in hFOB1.19 or MG-63 cell line compared with
homogenate. While mitochondrial was increased for 1.2
or 1.4-fold in upper phase and 6.9- or 6.3-fold in the
down phase in hFOB1.19 or MG-63 cell line. Basically,
the purification of PM was successful in both cell lines.
Identification of differentially expressed proteins
Since 2D-LC-MS/MS method provides a powerful alter-
native to gels especially in detecting hydrophobic pro-
teins, a newly developed iTRAQ technique was used here
to compare protein expression between MG-63 and
hFOB 1.19 cells. After duplicated LC-MS/MS analysis,
342 proteins were quantified, which had a p-values > 95%
confidence level (ProtScore > 1.3) and at least more than
one peptide above the 95% confidence level. 60 of them
were detected in both independent experiments, (Addi-
tional file 1). 66% (226 of 342) proteins were identified by
more than 5 peptides, 10% (36 out of 342) by 4 peptides;
11% (38 out of 342) by 3 peptides, 8% (27 out of 342) by 2
peptides and only 5%(17 out of 342)by one peptide (Addi-
tional file 2).
The following criteria were adopted: (1) cutoff iTRAQ
ratios of fold-change for protein expression were >1.5 for
up-regulation and <0.66 for down-regulation; (2) A pro-
tein had to be quantified with at least three spectra
(allowing generation of a p-value), a p-value < 0.05; (3) An
EF <2 was set for the quantification quality to be satisfied.
According to these criteria, a total of 68 differentially
expressed proteins were screened from the two experi-
ments. In the first experiment, 30 proteins were found to
be changed for more than 1.5-fold, including 10 proteins
up-regulated and 20 down-regulated with a p-value <
0.05. In the second, 48 proteins (P < 0.05) were changed,
21 proteins up-regulated and 27 down-regulated. Combi-
nation of two independent experiments showed 10 iden-
tified proteins including 6 up-regulated proteins and 4
down-regulated (as shown in Additional file 3). Represen-
tative MS/MS spectra for three peptides identified from
CD151 antigen are shown in Figure 2. Consistent changes
were found in the three peptides (Figure 2A, B and 2C).
Almost total y or b ions were detected in the sequence
(Figure 2D).
Bioinformatic analysis of differentially expressed proteins
Physicochemical characteristics of the identified Proteins
36% of these differential proteins are transmembrane
proteins, including 3 proteins with more than 10 trans-
membrane helices (TMHs),4 protein with 4 TMHs, 3
proteins with 2 TMHs, and 12 proteins with 1 TMH
(Additional file 3). Of the 79 differentially expressed pro-
teins, 13.0% hydrophobic proteins (with positive HP val-
ues up to 0.77) were identified (Additional file 3).
According to the annotations from UniProt knowledge-
base (Swiss-Prot/TrEMBL) and Gene Ontology Database,
68.1% (47 of 69) differential proteins located in plasma
membrane including proteins annotated as membrane,
single-pass type I membrane protein anchored to mem-
brane, intermediate filament, actin cytoskeleton, micro-
tubule, cell-cell adherent junction as well as plasma
membrane. The other proteins locate in other sub-cellu-
lar organelles such as nucleus (14.5%), cytoplasm (1.4%)
and endoplasmic reticulum (ER)-Golgi intermediate
(1.4%), or have unknown location (10 proteins) (Addi-
tional file 3, Figure 3A). Furthermore, we simply analyzed
the protein function annotated by GO database and
found that the following biological processes were more
frequently changed: proteins with binding activity
(including protein binding, ATP binding, DNA binding,
etc) (81.69%), cell structure (18.31%), and signal trans-
duction (18.31%) (Additional file 4, Figure 3B).
Protein-protein interaction analysis
Carcinogenesis is a very complex process and mediated
by a lot of proteins. In this work, we want to know how
PM proteins interact with each other and how they effect
cell's function in OS. To investigate these issues, we
searched the string database for protein interaction,
against proteins we identified as seeds. As shown in Fig-
ure 4, 52 seed proteins were involved protein-protein
interaction. Of which 21 were up-regulated proteins
Figure 1 Verification of PM through Western Blot. Fifty micro-
grams of homogenate, upper and down-phase proteins were separat-
ed in 11.5% SDS-PAGE and transferred to a PVDF membrane. The blots 
were probed with antibodies against organelle-specific proteins: anti-
Na+/K+-ATPase for PM; anti-prohibitin for mitochondria. Homo, U and 
D mean homogenate, upper-phase and down-phase respectively. 
"Nor" stands for hFOB1.19 and "MG" stand for MG-63. Na+/K+-ATPase 
enriched upper-phase was collected as PM.Zhang et al. BMC Cancer 2010, 10:206
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marked with "Δ", 31 were down-regulated highlighted by
"?". In the network, some proteins with consistent
changes interacts with each other, such as the down-reg-
ulated proteins (RAP1B-CTNNA1-PVRL2-IQGAP1 -
CTNNB1-CTNND1-ACTG1-FGR), the up-regulated
proteins (PLEC1-VIM-CD99- CD9-ANPEP-LGALS3-
LGALS1). However, in the all network, up-regulated pro-
teins usually interact with the down-regulated to consti-
tute a big network, for example, CD151 (Δ)-ITGA5 (?)-
ACTN1 (Δ)-CTNND1 (?). These seed proteins have
important function in signal transduction, cell adhesion,
etc. For example, CD151 can activate the PI3K pathway
and promote neovascularization via the PI3K pathway
[27]. CTNNB1 (Catenin beta-1, down-regulated in OS) is
involved in the regulation of cell adhesion and in signal
transduction through the Wnt pathway [28]. CTNND1
may regulate the cell adhesion properties of both C and
E-cadherin, and implicate both in cell transformation by
SRC and in ligand-induced receptor signaling through
the EGF [29].
According to the above bioinformatics analysis, CD151
antigen, was selected for further study due to 1) its PM
location; 2) hydrophobic character (HP of 0.33; TMHs of
4); 3) important function (having protein binding activity,
taking part in PI3K pathway and involving in protein-pro-
tein interaction (CD151, up-regulated; ITGA5, down-reg-
ulated).
Immunohistochemistry
Our differentially expressed proteins were detected in
established cell lines. To further verify the results
obtained from cell lines, an immunohistochemical study
was carried on OS tissue samples and their non-tumor-
ous adjacent tissue using anti-CD151 antibody. The rela-
tive positive signal in OS (Figure 5A) is much more than
that in the controls (Figure 5B). The semi-quantification
analysis showed that the expression of CD151 in OS and
its control is 57.9 ± 16.9% (n = 11) and 25.1 ± 13.1% (n =
11) respectively (Additional file 5, Figure 5C), which
revealed a good correlation between CD151 antibody
staining and the proteome expression profiles. Significant
difference between these OS and its controls (p = 0.0002)
was detected, with 2-fold up-regulated in OS according to
semi-quantitative analysis. This result validated our find-
ing from proteomic probing of differential plasma pro-
tein. CD151 may be a key molecule in regulating the
tumorigenesis and migration of osteosarcoma due to its
membrane protein function.
Discussion
Proteomics holds great promise in contributing to the
prevention and cure of cancer because it provides unique
tools for high-throughput screening of biomarkers and
therapeutic targets. As such, proteomics can help to
translate basic science discoveries into the clinical prac-
tice of personalized medicine [30,31]. However, its appli-
cation in osteosarcoma is very limited [4-8,32-36] due to
the difficulty in sample collection and protein extraction
directly from bone tissue. So far, there are only several
proteomic researches using osteosarcoma cell lines or
serum sample of OS patients. No sub-cellular proteomic
research of OS was found so far. Due to the complexity of
proteome in whole tissue or cells, many low abundant
proteins will be undetected, for example membrane pro-
Figure 2 MS and MS/MS spectra of CD151. Examples of MS and MS/MS spectra of a 3.67-fold up-regulated protein--CD151 antigen, illustrating the 
degree of relative quantitative measurement is consistency. MG-63 and hFOB 1.19 were labeled with 115- and 114- reporter isobaric reagent respec-
tively. Three quantified tryptic peptides (from a total of 5 non-redundant peptides) were shown in figure A, B and C. A, The MS spectra of a peptide-
TVVALCGQR with m/z of 568.81 (z = 2); B, The MS spectra of a peptide VEGGCITK, m/z = 570.80 and z = 2; C, The MS spectra of a peptide VVPDSCCK, 
m/z = 615.78 and z = 2. D, The MS/MS spectra of the peptide (VVPDSCCK), related b ion and y ion were shown.Zhang et al. BMC Cancer 2010, 10:206
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teins. Thus, in this study, we presented an OS plasma
membrane proteomic research combining differential
proteins identified in cell lines with differential protein
verification in tumor sample.
In order to identify more membrane proteins, iTRAQ™-
-stable isotope labeling, in conjunction with tandem MS
was used. iTRAQ is a high content proteomic technique
for substrate degradomics, can be used to label 4 or 8
samples simultaneously, and has been widely used in pro-
teomic research [37-39]. In our study, through comparing
the plasma membrane proteome of OS cell (MG-63) and
human osteoblastic cell (hFOB1.19), 342 proteins were
identified, including well known plasma membrane
markers such as sodium/potassium-transporting ATPase
subunit beta-3, 5'-nucleotidase precursor, Flotillin-1,
Voltage-dependent anion-selective channel protein 1 as
well as several CD antigen-CD151, CD55, CD81, CD63,
etc. In this work, 68 differentially expressed proteins were
identified, of which, 69.8% located in plasma membranes,
including CD151, CD99, etc. Consistent with previous
PM studies [22,40,41], we also identified non-PM pro-
teins in our PM because of the biochemical isolation of
PM and maybe the multiple locations of proteins. Fur-
ther, due to the use of iTRAQ combining LC-MS, 31.9%
of differentially expressed proteins have more than one
TMHs.
According to the annotation from GO database, the dif-
ferential proteins identified in this experiment function
as binding, signal transduction, immune response, and
angiogenesis, etc, and most might be involved in the fac-
tors related to cancer progress. The proteins with binding
function were mostly detected, and cell structure and sig-
nal transduction proteins were second most. We also
detected several differential proteins involved immune
r e s p o n s e  a s  w e l l  a s  p r o t e i n s  r e l a t e d  t o  a n g i o g e n e s i s .
These results indicated that following conclusion. First, it
is multi-factor progress for osteosarcoma development,
and many proteins are involved in. Second, proteins with
binding, cell structure, and signal transduction activities
are affected greatly in carcinogenesis. Finally, sub-cellular
Figure 3 Bioinformatic analysis of differentially expressed proteins. A. The sub-cellular location distribution, B. Function distribution graph of 
identified proteins. GO database were used for the data analysis.Zhang et al. BMC Cancer 2010, 10:206
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proteomic research can be used to find proteins related to
cancer.
Through bio-information analysis such as protein loca-
tion, function and protein-protein interaction, one pro-
tein--CD151 was selected for further verification.
Immunohistochemistry staining validated the up-regula-
tion of CD151 in OS. As annotated by UniProtKB/Swiss-
Prot registered as P48509, CD151 antigen, a multi-pass
membrane protein, interacts with integrins alpha3beta1,
alpha5beta1, alpha3beta1 and alpha6beta4, with CD9 and
CXCR1(CD181). CD151 functions as an important regu-
lator of communication between tumor cells and
endothelial cells, and might be as a potentially novel
prognostic marker and target for therapy in breast cancer
[16], biomarkers for assessment of malignancy in gingival
squamous cell carcinoma (GSCC) [42], renal cell carci-
noma [43] and metastasized colorectal carcinoma [18].
However, no research about CD151 in OS was reported
and this was the first report about its over-expression in
osteosarcoma cell line and sample, and can enlarge the
knowledge of CD151 in cancer. CD151 might be a poten-
tially novel biomarker and therapeutic target for OS. Fur-
ther functional experiments are worth doing.
Conclusions
To summary, in this work, we reported a sub-cellular pro-
teomic research combining PM purification, iTRAQ
label, LC-MS separation and identification in OS cell
lines with clinical verification in patient's tissues and
plasma. Many PM proteins with several TMs were
detected to be differentially expressed. CD151 were iden-
tified and verified to be a candidate of biomarker and
therapeutic target for OS. Our research might provide
some clue to understand the mechanism of OS progress
and offer novel biomarkers for OS diagnosis and treat-
ment.
Additional material
Additional file 1 Table S1-The list of all the proteins identified in this 
work. Two separated iTRAQ label plus mass spectrometry identification 
and quantification experiments were carried out in our study. Proteins iden-
tified twice are highlighted in bold italic letters.
Additional file 2 Table S2-The list of all the peptides detected by mass 
spectrometry. Only proteins with at least one peptide with confidence 
more than 95% were considered significant.
Figure 4 The protein-protein interaction network analyzed by 
String software.
Figure 5 Immunohistochemistry analyzing the expression of 
CD151. A. OS samples, B. Adjacent non-tumorous tissues. Immunore-
activity of CD151 was located in the plasma membrane. C. Semi-quan-
tification analysis of OS samples and adjacent non-tumorous tissues. 
Integrated optical density (IOD) are 57.9 ± 16.9% and 25.1 ± 13.1% re-
spectively (P = 0.0002). IOD of all positive staining in each photograph 
was measured by its ratio to total area.Zhang et al. BMC Cancer 2010, 10:206
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